Published in Medical Letter on the CDC and FDA, January 16th, 2005
The company expects to commence marketing its AtriLaze System via a direct U.S. sales force.
"This 510(k) clearance is just one more milestone achieved by the new management at MedicalCV," said Marc P. Flores, president and chief executive officer. "With a repopulation of management, 'right sizing' of the company, exiting the valve business, obtaining a 510(k) clearance on our AtriLaze System, and a directed focus into the atrial...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.